MED12 mutation frequency in unselected sporadic uterine leiomyomas.

Fertil Steril

Department of Medical Genetics, University of Helsinki, Helsinki, Finland; Genome-Scale Biology Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland. Electronic address:

Published: October 2014

Objective: To determine the frequency of mediator complex subunit 12 (MED12) mutations in well-documented, prospectively collected, unselected series of sporadic uterine leiomyomas to better understand the contribution of MED12 mutations in leiomyoma genesis.

Design: Mutation analysis of two prospectively collected sample series.

Setting: Department of gynecology in university hospital and medical genetics research laboratory.

Patient(s): 164 uterine leiomyomas from 28 patients (13 consecutive and 15 unselected patients) undergoing hysterectomy.

Intervention(s): MED12 mutation screening by direct sequencing, and clinical data collection.

Main Outcome Measure(s): MED12 mutation status and various clinical variables.

Result(s): MED12 mutations were found in 73 (83.0%) of 88 and 65 (85.5%) of 76 of uterine leiomyomas from the consecutive and unselected patient series, respectively. Smaller tumor size and a larger number of tumors correlated with positive MED12 mutation status.

Conclusion(s): The frequency of MED12 mutations in our prospectively collected uterine leiomyoma sets was higher than in previous works. This is in keeping with the concept that MED12 mutation-positive tumors tend to be smaller in size than MED12 mutation-negative tumors. The results highlight the central role of MED12 mutations in uterine leiomyoma genesis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fertnstert.2014.06.040DOI Listing

Publication Analysis

Top Keywords

med12 mutations
20
med12 mutation
16
uterine leiomyomas
16
prospectively collected
12
med12
11
sporadic uterine
8
consecutive unselected
8
uterine leiomyoma
8
uterine
6
mutations
5

Similar Publications

Purpose: Uterine leiomyomas (ULMs) are classified into those with and without MED12 mutations (MED12m(+) and MED12m(-), respectively). This study was undertaken to establish a culture system to evaluate the effect of female hormones on the growth of ULM cells in each ULM subtype.

Methods: ULM cells isolated from MED12m(+) or MED12m(-) tissues were cultured in a monolayer for 7 days with four hormone treatments: estrogen (E) and progesterone (P) (E + P), E only (E), P only (P), and medium only (CTRL).

View Article and Find Full Text PDF

Purpose: Cardiac angiosarcoma (CAS) is a rare, aggressive malignancy with limited treatment options. Both sporadic and familial cases occur, with recent links to germline POT1 mutations. The genomic landscape of this disease is poorly understood.

View Article and Find Full Text PDF

Uterine fibroids (UFs) are the most common non-cutaneous tumors in women worldwide. UFs arise from genetic alterations in myometrial stem cells (MM SCs) that trigger their transformation into tumor initiating cells (UF SCs). Mutations in the RNA polymerase II Mediator subunit MED12 are dominant drivers of UFs, accounting for 70% of these clinically significant lesions.

View Article and Find Full Text PDF

Uterine leiomyomas (uLMs) are the most prevalent benign tumors of the female reproductive system. MED12 is one of the mediator complex subunits that has been implicated in uLMs pathogenesis. Somatic mutations in exon2-MED12 have been found in ~ 70% of uLMs.

View Article and Find Full Text PDF
Article Synopsis
  • * A study analyzed 57 MPT samples using various genomic and immunohistochemical techniques, revealing low HER2 expression compared to common breast cancer, and identified frequent genetic alterations among different tumor sites.
  • * The research emphasizes the potential of next-generation sequencing (NGS) to find actionable genetic changes, supporting its role in MPT treatment decisions and highlighting the need for further MPT molecular studies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!